Procainamide Hydrochloride Capsules
» Procainamide Hydrochloride Capsules contain not less than 95.0 percent and not more than 105.0 percent of the labeled amount of C13H21N3O·HCl.
Packaging and storage— Preserve in tight containers.
Identification— Capsules respond to the Thin-Layer Chromatographic Identification Test 201, 5 µL of the clear supernatant used to prepare the Assay preparation in the Assay and 5 µL of the stock solution used to prepare the Standard preparation in the Assay being applied to the plate, and a solvent system consisting of a mixture of ethyl acetate, methanol, and ammonium hydroxide (22:2:1) being used to develop the chromatogram.
Dissolution 711
Medium: 0.01 N hydrochloric acid; 900 mL.
Apparatus 2: 50 rpm.
Time: 90 minutes.
Procedure— Determine the amount of C13H21N3O.HCl dissolved by employing UV absorption at the wavelength of maximum absorbance at about 275 nm on filtered portions of the solution under test, suitably diluted with an amount of 0.01 N sodium hydroxide that is not less than twice the volume of the portion of test solution taken, in comparison with a Standard solution having a known concentration of USP Procainamide Hydrochloride RS in the same media.
Tolerances— Not less than 75% (Q) of the labeled amount of C13H21N3O·HCl is dissolved in 90 minutes.
Uniformity of dosage units 905: meet the requirements.
Assay—
Mobile phase, Standard preparation, Resolution solution, and Chromatographic system— Prepare as directed in the Assay under Procainamide Hydrochloride.
Assay preparation— Accurately weigh and mix the contents of 20 Capsules. Transfer an accurately weighed portion of the mixture, equivalent to about 500 mg of procainamide hydrochloride, to a 500-mL volumetric flask. Add about 350 mL of methanol to the flask, and sonicate for 10 minutes in a 40 water bath. Allow the flask to cool to room temperature, dilute with methanol to volume, and mix. Centrifuge a portion of the suspension, transfer 5.0 mL of the clear supernatant obtained to a 100-mL volumetric flask, dilute with Mobile phase to volume, and mix. [note—Reserve the remainder of the clear supernatant for the Identification test.]
Procedure— Proceed as directed for Procedure in the Assay under Procainamide Hydrochloride. Calculate the quantity, in mg, of C13H21N3O·HCl in the portion of Capsule contents taken by the formula:
10,000C(rU / rS)
in which C is the concentration, in mg per mL, of USP Procainamide Hydrochloride RS in the Standard preparation, and rU and rS are the peak responses obtained from the Assay preparation and the Standard preparation, respectively.
Auxiliary Information— Please check for your question in the FAQs before contacting USP.
Topic/Question Contact Expert Committee
Monograph Sujatha Ramakrishna, Ph.D.
Scientist
1-301-816-8349
(MDCV05) Monograph Development-Cardiovascular
Reference Standards Lili Wang, Technical Services Scientist
1-301-816-8129
RSTech@usp.org
711 Margareth R.C. Marques, Ph.D.
Senior Scientist
1-301-816-8106
(BPC05) Biopharmaceutics05
USP32–NF27 Page 3388
Chromatographic Column—
Chromatographic columns text is not derived from, and not part of, USP 32 or NF 27.